Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. registers 15,164,724 shares of common stock for resale by selling stockholders in connection with its Nasdaq direct listing. The prospectus states the resale is not underwritten and that the company will receive no proceeds from sales by the selling stockholders. As of the date of the prospectus, 10,480,089 shares were issued and outstanding.
The prospectus discloses the company’s product focus on AI-powered blood tests (OneTest for Cancer and OneTest for Longevity), recent financial results including 2025 revenues of $2,045,133 and a net loss of $3,738,821, and risk factors related to commercialization, regulatory change, and liquidity.
20/20 Biolabs, Inc. granted Chief Financial Officer Alan B. Bergman a stock option covering 100,000 shares of common stock. The option has an exercise price of $1.88 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market purchase.
According to the vesting terms, 25,000 shares under the option vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months, as long as he continues to serve the company.
20/20 Biolabs, Inc. Chief Operating Officer Zhou Jiming received a grant of stock options covering 150,000 shares of Common Stock. The options have an exercise price of $1.88 per share, were granted on April 2, 2026, and expire on April 2, 2036. Following this grant, Zhou holds 150,000 stock options directly.
20/20 Biolabs, Inc. is registering 10,105,000 shares of common stock for resale by a single selling stockholder. The registered shares include previously issued stock, shares underlying a warrant, a secured convertible note, and series E convertible preferred stock. The company will not receive proceeds from share resales or conversions, only from any exercise of the warrant. 20/20 Biolabs develops AI-powered blood tests under the OneTest brand for multi-cancer early detection and chronic inflammation, operates a shared CLIA lab accelerator, and sells BioCheck field test kits. In 2025 it generated $2.0 million of revenue but recorded a net loss of $3.7 million and ended the year with a small stockholders’ deficit.
20/20 Biolabs, Inc. files a post-effective amendment to its Form S-1 to register 15,164,724 shares of common stock for resale by certain selling stockholders in connection with its direct listing.
The prospectus states these resales are by selling holders and the company will not receive proceeds from any sales. It notes 10,442,960 shares outstanding as of the date of this prospectus and discloses recent trading on Nasdaq under the symbol AIDX.
20/20 BioLabs, Inc. reported full year 2025 results with revenue of $2.0 million, up 17% from 2024. Gross profit rose to $0.6 million and gross margin expanded to 29.6% from 20.6%, helped by a higher mix of BioCheck and CLIAX revenue.
Operating expenses fell to $3.9 million from $6.0 million, improving the net loss to $3.7 million from $5.6 million. Cash was $1.0 million at year-end 2025, and in February 2026 the company closed a $5.0 million tranche under a preferred purchase agreement that could total up to $40 million. Management highlights a state-funded firefighter cancer screening program, deferred revenue of about $0.5 million, the launch of OneTest for Longevity and a recent Nasdaq listing as positioning the company for 2026 growth.
20/20 Biolabs, Inc. focuses on AI-powered blood tests for early detection and prevention of cancers and chronic diseases. Its main product, OneTest for Cancer, is a multi‑cancer early detection blood test run in a CAP‑accredited, CLIA‑licensed lab and positioned as an affordable “top‑of‑funnel” screen using protein tumor markers and machine learning.
The company added OneTest for Longevity in 2026 to track inflammatory biomarkers linked to chronic diseases and provide diet and lifestyle guidance using the Dietary Inflammatory Index. It also operates a Clinical Laboratory Innovation Accelerator to host third‑party lab‑developed tests and sells BioCheck field kits for suspicious powders. OneTest for Cancer generated 88% of 2025 revenue, with total shares outstanding rising to 10,442,960 as of March 30, 2026.
20/20 Biolabs, Inc. joint Schedule 13G discloses that Full Succeed International Limited is the record holder of 651,465 shares of common stock, representing 6.3% of the class based on 10,347,232 shares outstanding as of February 19, 2026. The statement is jointly filed by Full Succeed, and its directors Nengyuan Pan and Wei Lu, who share voting and dispositive power over the shares held by Full Succeed. Each individual disclaims beneficial ownership except for any pecuniary interest. The joint filing is signed and includes a Joint Filing Agreement.